OverviewSuggest Edit

Sophiris is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments.

TypePublic
Founded2002
HQSan Diego, US
Websitesophirisbio.com

Latest Updates

Employees (est.) (Dec 2018)6
Revenue (FY, 2013)$5 M
Share Price (Sept 2020)$0
Cybersecurity ratingAMore

Key People/Management at Sophiris

Randall E. Woods

Randall E. Woods

President and CEO
Allison Hulme

Allison Hulme

COO & Head of R&D
Peter T. Slover

Peter T. Slover

Chief Financial Officer
Lars Ekman

Lars Ekman

Chairman
John Geltosky

John Geltosky

Director
Gerald T. Proehl

Gerald T. Proehl

Director
Show more

Sophiris Office Locations

Sophiris has an office in San Diego
San Diego, US (HQ)
1258 Prospect St, La Jolla
Show all (1)

Sophiris Financials and Metrics

Sophiris Revenue

Sophiris's revenue was reported to be $5 m in FY, 2013
USD

Net income (Q3, 2019)

(959.0k)

Market capitalization (22-Sept-2020)

401.6k

Closing stock price (22-Sept-2020)

0.0

Cash (30-Sept-2019)

4.3m

EV

1.9m
Sophiris's current market capitalization is $401.6 k.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

5.0m

General and administrative expense

4.5m5.3m3.6m6.8m5.7m4.4m

R&D expense

10.3m24.7m9.9m3.5m6.2m10.7m

Operating expense total

14.8m30.0m13.5m10.3m11.9m15.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

General and administrative expense

883.0k1.5m1.5m1.4m1.0m997.0k921.0k1.2m1.4m3.0m1.4m1.4m1.7m1.2m1.1m1.2m1.3m1.2m1.4m

R&D expense

2.1m6.8m7.1m6.7m3.1m2.6m2.6m929.0k978.0k624.0k1.2m1.4m1.6m3.3m3.6m1.8m1.6m1.1m738.0k

Operating expense total

3.0m8.3m8.6m8.1m4.1m3.6m3.5m2.1m2.3m3.7m2.6m2.8m3.3m4.6m4.7m3.0m2.8m2.3m2.1m

Depreciation and amortization

5.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.8m4.1m5.9m12.8m16.1m11.0m

Accounts Receivable

48.0k16.0k8.0k128.0k13.0k

Prepaid Expenses

3.6m2.8m467.0k846.0k999.0k656.0k

Current Assets

51.8m25.5m8.9m30.0m26.9m13.2m
USDQ3, 2013

Financial Leverage

1.3 x
Show all financial metrics

Sophiris Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Sophiris Online and Social Media Presence

Embed Graph

Sophiris News and Updates

Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of...

Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering

SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (Nasdaq: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of...

Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

SAN DIEGO and VANCOUVER, British Columbia, Nov. 13, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of...

Sophiris Bio to Present at the Cantor Global Healthcare Conference

SAN DIEGO and VANCOUVER, British Columbia, Sept. 25, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of...

Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement

SAN DIEGO and VANCOUVER, British Columbia, Sept. 14, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of...

Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference

SAN DIEGO and VANCOUVER, British Columbia, Aug. 29, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of...
Show more

Sophiris Frequently Asked Questions

  • When was Sophiris founded?

    Sophiris was founded in 2002.

  • Who are Sophiris key executives?

    Sophiris's key executives are Randall E. Woods, Allison Hulme and Peter T. Slover.

  • How many employees does Sophiris have?

    Sophiris has 6 employees.

  • Who are Sophiris competitors?

    Competitors of Sophiris include Beacon Clinical Research, BlackThorn Therapeutics and NanoVelos.

  • Where is Sophiris headquarters?

    Sophiris headquarters is located at 1258 Prospect St, La Jolla, San Diego.

  • Where are Sophiris offices?

    Sophiris has an office in San Diego.

  • How many offices does Sophiris have?

    Sophiris has 1 office.